Extracorporeal removal of microvesicular particles
Inventors
Ichim, Thomas • Tullis, Richard H.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9364601-B2
Publication Date
2016-06-14
Expiration Date
Abstract
The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.
Core Innovation
The patent describes extracorporeal removal of microvesicles and exosomes from systemic circulation to address immune suppression in cancer. It identifies exosomes as microvesicular particles and states that captured exosomes can be removed from patient circulation using surfaces and devices configured to bind exosomes selectively or non-selectively.
The invention provides systems and devices for capturing exosomes using affinity agents including lectins and other affinity molecules. It describes contacting exosomes with an affinity absorbent or a surface comprising a lectin, thereby capturing the exosome on the lectin-containing surface or absorbent.
The affinity absorbent is provided as matrices such as porous membranes and bead or other support formats. The document further describes related immune-modulating embodiments, including potentiating cancer vaccine responses and enhancing immune cell functions, and includes affinity capture contexts involving Fas ligand and multiple targets such as MHC I, MHC II, and CD44.
Claims Coverage
The partial content includes two independent claims directed to capturing exosomes from a patient using lectin-containing capture surfaces or lectin-containing affinity devices. Across both independent claims, the inventive features focus on patient-derived exosome capture via lectin affinity and implementation on a lectin-bearing surface or within an affinity device comprising a lectin-containing affinity absorbent.
Patient-identified lectin surface for exosome capture
identifying a patient for exosome capture and contacting an exosome from said patient with a surface that comprises a lectin thereby capturing said exosome
Affinity device with lectin affinity absorbent
contacting an exosome from said patient with an affinity device that comprises an affinity absorbent comprising a lectin thereby capturing said exosome on the affinity absorbent
Both independent claims are centered on capturing patient-derived exosomes by contacting them with a lectin-containing capture component, either as a lectin-containing surface or as a lectin-containing affinity absorbent within an affinity device.
Stated Advantages
Reversing cancer-associated immune suppression.
Potentiating cancer vaccine responses.
Enhancing immune cell functions.
Documented Applications
Extracorporeal removal of microvesicles and exosomes from systemic circulation to reverse cancer-associated immune suppression.
Use in embodiments for potentiating cancer vaccine responses and enhancing immune cell functions.
Capturing exosomes using lectin-containing capture surfaces or affinity devices for a patient having cancer [procedural detail omitted for safety].
Capturing exosomes in extracorporeal circulation scenarios described as including plasmapheresis/filtration approaches [procedural detail omitted for safety].
Interested in licensing this patent?